FDA Officials Point Out Interchangeability Essential to Biosimilar Competition
November 8, 2022
Despite a range of biosimilars entering the market, their ability to lower drug spending for patients is dependent on payer reimbursement, which is inconsistent and based on approved uses. According to FDA officials, one avenue to ease these issues is with interchangeables, drugs that can be substituted without a doctor’s permission. However, only a few of these drugs have been approved for interchangeable use. The market landscape is shaky, even for approved interchangeables like Semglee by Viatris, an insulin biosimilar.
According to , “But as proof of how wonky the biosimilar reimbursement landscape can be, and how even an interchangeability designation doesn’t necessarily mean immediate uptake, Viatris had to launch multiple versions of Semglee, one with a modest discount and one that’s more expensive but with a higher rebate.”
To read more, click here.
(Source: Endpoints News, November 8th, 2022)
